A Rangel1, B Race, J Striebel, B Chesebro. 1. Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, MT 59840, USA.
Abstract
AIMS: Prion diseases are characterized by brain deposits of misfolded aggregated protease-resistant prion protein (PrP), termed PrPres. In humans and animals, PrPres is found as either disorganized non-amyloid aggregates or organized amyloid fibrils. Both PrPres forms are found in extracellular spaces of the brain. Thus, both might block drainage of brain interstitial fluid (ISF). The present experiments studied whether ISF blockage occurred during amyloid and/or non-amyloid prion diseases. METHODS: Various-sized fluorescein-labelled ISF tracers were stereotactically inoculated into the striatum of adult mice. At times from 5 min to 77 h, uninfected and scrapie-infected mice were compared. C57BL/10 mice expressing wild-type anchored PrP, which develop non-amyloid PrPres similar to humans with sporadic Creutzfeldt-Jakob disease, were compared with Tg44+/+ mice (transgenic mice secreting anchorless PrP) expressing anchorless PrP, which develop amyloid PrPres similar to certain human familial prion diseases. RESULTS: In C57BL/10 mice, extensive non-amyloid PrPres aggregate deposition was not associated with abnormal clearance kinetics of tracers. In contrast, scrapie-infected Tg44+/+ mice showed blockage of tracer clearance and colocalization of tracer with perivascular PrPres amyloid. CONCLUSIONS: As tracer localization and clearance was normal in infected C57BL/10 mice, ISF blockage was not an important pathogenic mechanism in this model. Therefore, ISF blockage is unlikely to be a problem in non-amyloid human prion diseases such as sporadic Creutzfeldt-Jakob disease. In contrast, partial ISF blockage appeared to be a possible pathogenic mechanism in Tg44+/+ mice. Thus this mechanism might also influence human amyloid prion diseases where expression of anchorless or mutated PrP results in perivascular amyloid PrPres deposition and cerebral amyloid angiopathy. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
AIMS: Prion diseases are characterized by brain deposits of misfolded aggregated protease-resistant prion protein (PrP), termed PrPres. In humans and animals, PrPres is found as either disorganized non-amyloid aggregates or organized amyloid fibrils. Both PrPres forms are found in extracellular spaces of the brain. Thus, both might block drainage of brain interstitial fluid (ISF). The present experiments studied whether ISF blockage occurred during amyloid and/or non-amyloid prion diseases. METHODS: Various-sized fluorescein-labelled ISF tracers were stereotactically inoculated into the striatum of adult mice. At times from 5 min to 77 h, uninfected and scrapie-infectedmice were compared. C57BL/10 mice expressing wild-type anchored PrP, which develop non-amyloid PrPres similar to humans with sporadic Creutzfeldt-Jakob disease, were compared with Tg44+/+ mice (transgenic mice secreting anchorless PrP) expressing anchorless PrP, which develop amyloid PrPres similar to certain humanfamilial prion diseases. RESULTS: In C57BL/10 mice, extensive non-amyloid PrPres aggregate deposition was not associated with abnormal clearance kinetics of tracers. In contrast, scrapie-infectedTg44+/+ mice showed blockage of tracer clearance and colocalization of tracer with perivascular PrPres amyloid. CONCLUSIONS: As tracer localization and clearance was normal in infected C57BL/10 mice, ISF blockage was not an important pathogenic mechanism in this model. Therefore, ISF blockage is unlikely to be a problem in non-amyloid humanprion diseases such as sporadic Creutzfeldt-Jakob disease. In contrast, partial ISF blockage appeared to be a possible pathogenic mechanism in Tg44+/+ mice. Thus this mechanism might also influence human amyloid prion diseases where expression of anchorless or mutated PrP results in perivascular amyloid PrPres deposition and cerebral amyloid angiopathy. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Authors: A Popa-Wagner; D Pirici; E B Petcu; L Mogoanta; A-M Buga; C L Rosen; R Leon; J Huber Journal: Curr Neurovasc Res Date: 2010-08 Impact factor: 1.990
Authors: Mikael Klingeborn; Brent Race; Kimberly D Meade-White; Rebecca Rosenke; James F Striebel; Bruce Chesebro Journal: J Virol Date: 2010-12-01 Impact factor: 5.103
Authors: Cheryl A Hawkes; Wolfgang Härtig; Johannes Kacza; Reinhard Schliebs; Roy O Weller; James A Nicoll; Roxana O Carare Journal: Acta Neuropathol Date: 2011-01-23 Impact factor: 17.088
Authors: Casper Jansen; Piero Parchi; Sabina Capellari; Ad J Vermeij; Patrizia Corrado; Frank Baas; Rosaria Strammiello; Willem A van Gool; John C van Swieten; Annemieke J M Rozemuller Journal: Acta Neuropathol Date: 2009-11-13 Impact factor: 17.088
Authors: Bruce Chesebro; Brent Race; Kimberly Meade-White; Rachel Lacasse; Richard Race; Mikael Klingeborn; James Striebel; David Dorward; Gillian McGovern; Martin Jeffrey Journal: PLoS Pathog Date: 2010-03-05 Impact factor: 6.823
Authors: James A Carroll; James F Striebel; Alejandra Rangel; Tyson Woods; Katie Phillips; Karin E Peterson; Brent Race; Bruce Chesebro Journal: PLoS Pathog Date: 2016-04-05 Impact factor: 6.823